Related by context. All words. (Click for frequent words.) 73 Phase 2b clinical 72 pivotal Phase III 71 phase IIb clinical 71 phase IIa clinical 71 Phase 2a clinical 70 Phase III clinical 70 phase IIb 70 Phase Ib 70 SUCCEED trial 69 Phase IIb clinical 69 Phase IIa trial 69 Phase #b/#a clinical 69 APEX PD 68 Phase IIIb clinical 68 confirmatory Phase III 68 Phase 2a trial 68 Phase 2b study 68 phase IIa 68 Phase 2b clinical trials 68 Phase III pivotal 68 Phase IIb trial 68 Phase 2a 67 Phase Ib study 67 Phase IIb trials 67 Phase III 67 Phase 1b trial 67 BLA filing 67 phase Ib clinical 67 Phase IIb 67 MAA submission 66 oral ridaforolimus 66 Phase 2b trial 66 pivotal Phase 66 Phase IIa clinical 66 Phase IIa trials 66 Phase 2b 66 registrational trial 66 Phase III clinical trials 66 Phase 1b clinical 66 European Sepsis Trial 66 registrational 66 Phase IIb clinical trials 65 IIa trial 65 Phase 1a clinical 65 BCX# 65 sNDA submission 65 Phase 1b dose escalation 65 Phase Ib II 65 alvespimycin 65 HCD# [002] 65 Phase Ib IIa 65 BLA submission 65 phase 2a 65 forodesine 65 phase IIb trial 65 Phase 1b 65 Phase II 65 AeroLEF TM 65 Aurexis 65 generation URAT1 inhibitor 65 Phase IIa 64 ongoing Phase 1b 64 Phase #b/#a 64 FOLOTYN ® 64 Phase III confirmatory 64 GALNS 64 Phase 1a 64 phase IIb study 64 BRIM3 64 JAK inhibitor 64 Phase IIB 64 pivotal bioequivalence 64 Phase 2b kidney transplant 64 Phase Ib clinical trials 64 Phase Ib clinical 64 phase Ib 64 Cloretazine ® 64 oral prodrug 64 INCB# [001] 64 PLK1 SNALP 64 Phase IIb III 63 LibiGel Phase III 63 PEG PAL 63 Phase IIB clinical 63 Bicifadine 63 Phase IIIb 63 GetGoal Phase III 63 PEG SN# 63 ENRICH trial 63 CB2 selective receptor agonist 63 torezolid phosphate 63 Allovectin 7 63 initiate Phase IIb 63 Phase III trials 63 Zerenex 63 multicenter Phase 63 TOCOSOL Paclitaxel 63 Androxal TM 63 Phase Ia 63 Zenvia Phase III 62 Phase IIa clinical trials 62 Dacogen injection 62 PRX # 62 PREOS R 62 R#/MEM # 62 placebo controlled Phase 62 Phase #/#a 62 EDEMA4 62 IND submission 62 PANVAC VF 62 Corlux 62 Phase III HEAT 62 rALLy trial 62 OLpur TM H2H 62 leading oral taxane 62 IND enabling 62 dirucotide 62 GLP toxicology studies 62 Ketotransdel 62 placebo controlled clinical 62 EDEMA3 62 Fodosine 62 investigational pan BCR 62 NDA submission 62 Investigational Device Exemption IDE 62 lomitapide 62 viral kinetic 62 Phase 1b clinical trials 62 AP# [003] 62 COMFORT II 62 AIMM trial 62 IMA# 62 Fibrillex TM 62 PSMA ADC 62 Phase III Pivotal 62 Omigard 62 OvaRex R 62 alvimopan 62 lorcaserin Phase 62 trastuzumab DM1 T DM1 61 RSD# oral 61 apricitabine ATC 61 tezampanel 61 Besivance 61 brentuximab vedotin SGN 61 Zenvia ™ 61 randomized controlled Phase 61 MERLIN TIMI 61 Plicera 61 ganetespib 61 Pivotal Phase III 61 Phase lll 61 Phenoptin 61 PRECISE Trial 61 dose escalation Phase 61 SYMMETRY trial 61 confirmatory pivotal 61 dose escalation trial 61 ATryn R 61 Nasdaq PGNX today 61 relapsed refractory multiple myeloma 61 MEND CABG II 61 randomized Phase 2b 61 peginesatide 61 dose cohort 61 multiple ascending dose 61 vosaroxin 61 Archexin 61 CEQ# 61 oral calcitonin 61 pharmacokinetic PK study 61 Anturol TM 61 TASKi2 61 MEND CABG 61 PROPEL trial 61 ICA # 61 CR# vcMMAE 61 Allovectin 7 R 61 unique alkylating agent 61 Panzem R NCD 61 MAGE A3 ASCI 61 INCB# [002] 61 ANCHOR trial 61 PFO migraine 61 Shigamabs ® 61 elagolix 61 Shigamabs R 61 QNEXA 61 Phase III LibiGel 61 Phase III psoriasis 61 pseudobulbar affect PBA 61 Phase III Clinical Trial 61 TMC# C# 61 huC# DM4 61 candidate XP# 61 deforolimus 61 LUMINATE 61 PDX pralatrexate 61 CLIRS trial 60 EmbraceAC 60 Panzem R 60 VITAL Trial 60 REVIVE Diabetes 60 LibiGel ® testosterone gel 60 tanespimycin 60 Glybera R 60 Stedivaze 60 BRIM2 60 ENDEAVOR III 60 CIP ISOTRETINOIN 60 phase IIb III 60 GED aPC 60 bile duct tumor 60 MAXY alpha 60 randomized Phase IIb 60 ZYBRESTAT fosbretabulin 60 Phase 2a clinical trials 60 PDE4 inhibitor 60 KNS # 60 Phase 2b Clinical Trial 60 glufosfamide 60 Pivotal Phase 60 IMGN# 60 ENDEAVOR IV 60 PXD# 60 SILENOR TM 60 Allovectin 7 ® 60 ADVANCE PD 60 MGCD# [001] 60 Restanza 60 Cloretazine R VNP#M 60 confirmatory clinical 60 CHAMPION PCI 60 Testosterone MDTS ® 60 pradefovir 60 drug pipeline TAFA# 60 LE SN# 60 AZX# 60 octreotide implant 60 midstage trials 60 sodium Injection 60 phase IIIb 60 rALLy clinical trial 60 compound INCB# 60 blinded randomized placebo controlled 60 multicenter clinical 60 PMA submission 60 GATTEX ® 60 EXPLORE Xa 60 Investigational Device Exemption 60 placebo controlled Phase III 60 tesmilifene 60 SPIRIT FIRST 60 dose escalation phase 60 fidaxomicin Phase 60 Surfaxin LS 60 Anturol 60 IIb clinical trial 60 lorvotuzumab mertansine 59 LUVENIQ 59 NP2 Enkephalin 59 CUSTOM III 59 elotuzumab 59 ruxolitinib 59 APPRAISE 59 MOZOBIL 59 TACI Ig 59 Quinamed 59 Azedra 59 randomized controlled multicenter 59 Spiegelmer ® 59 bicifadine 59 Virulizin ® 59 dosing cohort 59 AQ4N 59 ongoing Phase IIIb 59 acyclovir Lauriad R 59 dalbavancin 59 Application BLA 59 investigational humanized monoclonal antibody 59 Alzhemed TM 59 lintuzumab SGN 59 Phase IIb kidney transplant 59 SinuNase 59 HCV protease inhibitor 59 ABSORB clinical 59 opioid induced bowel dysfunction 59 talactoferrin 59 dose escalation clinical 59 MBP# [001] 59 CRMD# 59 ELACYT 59 arzoxifene 59 clinical pharmacology studies 59 dextromethorphan quinidine 59 Iluvien ® 59 budesonide foam 59 phase III ACCLAIM 59 UVIDEM 59 MIST II 59 randomized Phase III 59 ponatinib 59 TKB# 59 Amigal 59 LymphoStat B 59 UPLYSO 59 indiplon capsules 59 diabetic neuropathic pain 59 Fx #A 59 NGX# 59 anticancer compound 59 PRESEPT 59 Zelrix 59 incyclinide 59 Tanespimycin 59 zanolimumab 59 LymphoStat B belimumab 59 GAMMAGARD 59 IL# PE#QQR 59 Dextofisopam 59 clinicaltrials 59 Phase III randomized controlled 59 APEX AMI trial 59 XL# XL# XL# XL# 59 Veronate 59 lintuzumab 59 Azedra TM 59 Albuferon Phase 59 Anturol ® 59 Initiate Phase 59 Rhucin ® 59 randomized Phase 59 XL# anticancer compounds 59 hypoxia activated prodrug 59 Augment Injectable 59 OncoVEX 59 Icatibant 59 orBec 59 HspE7 59 Zenvia TM 59 TBC# 59 LUX Lung 59 NUVIGIL 59 Oral NKTR 59 initiated Phase Ib 59 Locteron ® 59 ONCONASE 59 Urocidin 59 Fast Track designation 59 Traficet EN 59 Thorough QT 59 MoxDuo IR 59 Aryplase 59 orally administered inhibitor 59 T Pred 59 HGS# 59 Genasense ® oblimersen 59 evaluating Actimmune 59 Soliris TM eculizumab 59 ILUVIEN ® 59 Azedra ™ 59 Perifosine 59 Maximum Tolerated Dose MTD 59 eniluracil 59 CIP TRAMADOL ER 59 ARISE Phase III 58 immunosuppressive compound 58 ALN RSV# 58 Bezielle 58 ALN VSP Phase 58 Carfilzomib 58 VEGF Trap 58 fund BioSante LibiGel 58 XL# XL# XL# 58 fidaxomicin Phase 3 58 selective androgen receptor modulator 58 HepeX B TM 58 double blinded placebo 58 thorough QT 58 Amrubicin 58 EOquin TM 58 Pivotal Trial 58 HuMax EGFr 58 BEMA Granisetron 58 Ganite ® 58 oral deforolimus 58 Diabetic Macular Edema 58 Troxatyl 58 Phase III placebo controlled 58 candidate brentuximab vedotin 58 refractory Hodgkin lymphoma 58 exemption IDE 58 EGS# 58 label dose escalation 58 formal pharmacokinetic PK 58 PREGNANT Study 58 FavId 58 Probuphine 58 Nuvion 58 Tarvacin TM 58 liprotamase 58 LEUKINE 58 oral picoplatin 58 IND Investigational New 58 seliciclib CYC# 58 Phase #/#a clinical 58 Luveniq 58 EXPAREL ™ 58 controlled multicenter 58 Genasense ® 58 denufosol 58 Hedgehog antagonist 58 novel VDA molecule 58 R#/MEM 58 virus HCV protease inhibitor 58 enzastaurin 58 Biologics License Application 58 Civacir 58 non nucleoside HCV 58 preclinical pharmacokinetic 58 Board DSMB 58 MEK inhibitor RDEA# 58 IoGen 58 Hematide ™ 58 Marketing Authorization Application MAA 58 tezampanel NGX# 58 Topical Interferon Alpha 2b 58 brivaracetam 58 Phase IIb Clinical Trial 58 CCX# 58 Forodesine HCl 58 PROVENGE ® 58 PS# [001] 58 Allovectin 7 r 58 ularitide 58 SNT MC# 58 clinical trial 58 vidofludimus 58 CCR5 mAb 58 Vertex Pharma 58 Protexia ® 58 tramiprosate Alzhemed TM 58 unblinding 58 Biologics License Application BLA 58 EndoTAG TM -1 58 telomerase inhibitor drug 58 novel histone deacetylase 58 NO# [002] 58 Ocrelizumab 58 TELCYTA 58 candidate AQ4N 58 successfully commercialize Iluvien 58 pharmacokinetic PK 58 LibiGel ® 58 forodesine HCl 58 THALOMID 58 SparVax TM 58 Cutanea Life Sciences 58 HepeX B 58 Sulonex TM 58 mGluR5 negative 58 AEG# 58 refractory chronic lymphocytic 58 dextofisopam 58 Æterna Zentaris 58 Gabapentin GR 58 dimebon 58 ENESTnd 58 AVADO 58 StemEx 58 oral methylnaltrexone 58 omacetaxine mepesuccinate 58 PNP inhibitor 58 custirsen 58 initiated Phase 1b 58 multicenter randomized placebo controlled 58 IIa clinical 58 Vicriviroc 58 ITAX 58 nonclinical studies 58 Asentar 58 HuMax CD4 58 generation purine nucleoside 58 mertansine 58 Lovaxin C 58 Daclizumab 58 Trofex 58 HGS ETR1 58 PRT# 58 Loramyc R 58 Xcellerated T Cells 58 initiate Phase 1b 58 glucokinase activator 58 Genasense R oblimersen 58 MDV# 58 oxymorphone ER 58 EOquin 58 LymphoStat B TM 58 candidate CRLX# 58 COSIRA trial 58 ThermoDox ® clinical 58 KRYSTEXXA TM pegloticase 58 Ophena TM 57 mGluR5 NAM 57 Xcytrin R 57 Phase III ADT 57 TOLAMBA 57 IDX# 57 ANYARA 57 XmAb# 57 Phase 57 AZX# Phase 57 Ixempra 57 L BLP# 57 Tarceva TM 57 JZP 57 TKM ApoB 57 evaluating tivozanib 57 TEMSO 57 AzaSite Plus 57 sapacitabine 57 systemic Phase 1b 57 CORLUX 57 controlled multicenter Phase 57 Tesetaxel 57 sunitinib malate 57 ulimorelin 57 cannabinor 57 Aurora kinase inhibitor 57 NADiA ProsVue 57 investigational compound 57 LEP ETU 57 Exherin TM 57 generation proteasome inhibitor 57 transmucosal delivery system 57 celgosivir 57 Amoxicillin PULSYS Phase III 57 Acetavance TM intravenous acetaminophen 57 Biologic License Application BLA 57 rhC1INH 57 Dyloject TM 57 Phase 2b randomized 57 MIVI III 57 BrachySil TM 57 ORE# 57 TG MV 57 preclinical toxicology 57 ENDEAVOR IV clinical 57 GATTEX ™ 57 ATryn ® 57 IMPACT IMmunotherapy 57 OvaRex ® MAb 57 Phase IIIb study 57 MEK inhibitor 57 denosumab oncology 57 rNAPc2 57 Flutiform ™ 57 Special Protocol Assessment 57 PHX# 57 NVA# 57 Pimavanserin 57 bardoxolone 57 PEARL SC 57 R# #mg BID 57 ToGA 57 PRIMO CABG 57 double blinded randomized 57 initiate Phase Ib 57 tolevamer 57 FORTIS M trial 57 rPA anthrax vaccine 57 dirucotide MBP# 57 pralatrexate injection folate analogue 57 OncoVEX GM CSF 57 evaluating mipomersen 57 PROMACTA 57 SILENOR 57 Personalized Immunotherapy 57 initiate multicenter 57 RSD# iv 57 Octreolin 57 Sym# 57 Glybera 57 Phase III metastatic melanoma 57 StaphVAX R 57 severe hypercholesterolemia 57 ABL inhibitor 57 velafermin belinostat 57 multicenter randomized Phase 57 ridaforolimus 57 Phase IIb Trial 57 aplindore 57 Trofex TM 57 PROVENGE sipuleucel T 57 Vicinium TM 57 IMC A# 57 MyVax R 57 MAP# 57 MKC# MT 57 dose escalation study 57 ONCONASE R 57 Virulizin R 57 OMS#HP 57 ApoB SNALP 57 Solazed TM 57 BAY #-# 57 prGCD 57 AZD# TC 57 QLT# 57 Trofex ™ 57 trastuzumab emtansine T DM1 57 axitinib 57 Phase III multicenter 57 Regeneron Pharma 57 Oracea TM 57 CAMPATH 57 neurogenic orthostatic hypotension 57 APTIVUS 57 VALOR trial 57 dacetuzumab SGN 57 nalbuphine ER 57 interferon gamma 1b 57 QNEXA ® 57 IMC #B 57 Celacade TM technology 57 Hyphanox 57 Glufosfamide 57 Initiated Phase 57 BEMA TM Fentanyl 57 novel oral anticoagulant 57 Annamycin 57 labial herpes 57 teriflunomide 57 targeted radiotherapeutic 57 Aflibercept 57 vernakalant oral 57 SAR# [004] 57 cariprazine 57 pralatrexate injection 57 NEBIDO 57 DSMB recommended 57 alogliptin 57 Urocortin 2 57 midstage studies 57 ZEGERID Capsules 57 Hsp# Inhibitor 57 Fast Track Status 57 Empatic 57 TRANSDUR ™ 57 PEG Interferon lambda 57 voreloxin 57 Marketing Authorization Application 57 PRECISE trial 57 ORBIT II 57 non nucleoside inhibitor 57 individualized cellular immunotherapy 57 granted Ortec 57 P#X# antagonist 57 MONOVISC 57 MAXY G# 57 treatment naive genotype 57 Sulonex 57 ACCLAIM II 57 Marqibo 57 APF# 57 product platforms AZX# 57 Locteron 57 mg/m2 cohort 57 Entereg R 57 XOMA 3AB 57 Combination REOLYSIN R 57 MKC# MKC# PP 57 PIX# [002] 57 aclidinium bromide 57 Iloperidone 57 HGS ETR2 57 Cimzia TM 57 BLOOM Behavioral modification 57 neratinib 57 Inc. Nasdaq VVUS 57 Elagolix 56 BrachySil 56 ALN PCS 56 blinatumomab 56 YONDELIS 56 Synavive 56 Neuradiab 56 CLARITY study 56 PSN# [002] 56 OPT CHF 56 romidepsin novel 56 TMC# [002] 56 adecatumumab MT# 56 confirmatory Phase 56 Xanafide 56 Q#IR 56 Nexavar ® 56 Biologic License Application 56 ataluren 56 huN# DM1 56 dose escalation 56 class mGluR5 inhibitor 56 Staccato loxapine 56 CURE AF 56 bevirimat Study 56 HCV SPRINT 56 AeroLEF 56 next generation URAT1 56 RAPTIVA 56 GATTEX TM 56 Phase #/#a trial 56 Phase #b/#a trial 56 dependent kinase inhibitor 56 Lymphoseek ® 56 Solazed 56 vilazodone 56 Plenaxis TM 56 Lucanix R 56 initiate Phase 2b 56 Telaprevir 56 INT# [002] 56 aclidinium 56 pharmacokinetic studies 56 EMPOWER ™ 56 Prostate AdenoCarcinoma Treatment 56 budesonide MMX Phase III 56 apaziquone 56 Ceflatonin R 56 PRTX 56 dacetuzumab 56 liposomal formulation 56 EDEMA3 trial 56 palifosfamide Zymafos TM 56 Phase 2b monotherapy 56 Phase III ThermoDox 56 Inhalation Solution 56 Lung Rx 56 postoperative ileus POI 56 tiapamil 56 Raptiva ® 56 GOUT 56 TELINTRA 56 BEMA Buprenorphine 56 reslizumab 56 Kamada AAT 56 multicenter Phase II 56 Tarsa Therapeutics 56 EVIZON TM squalamine lactate 56 Completes Patient Enrollment 56 NDA resubmission 56 Cimzia ® certolizumab pegol 56 Serada 56 Diamyd ® 56 Excellarate TM 56 evaluating REVLIMID 56 ABSORB trial 56 Drug Eluting Stent System 56 Staphylococcus aureus Polysaccharide Conjugate 56 RIGScan CR 56 PRIMO CABG2 56 Phase III Clinical Trials 56 severe gastroparesis 56 Entereg TM 56 ozarelix 56 maribavir 56 XL# [003] 56 Intermezzo ® NDA 56 tremelimumab 56 teduglutide 56 BST CarGel R 56 ALN VSP 56 LymphoStat B Phase 56 AIR CF1 56 Intermezzo R 56 MAb therapy 56 preclinical 56 dose cohorts 56 refractory multiple myeloma 56 ROCKET AF 56 ProSavin 56 Targretin capsules 56 OMAPRO 56 ELADUR ™ 56 ZYBRESTAT TM 56 OHR/AVR# 56 ZYBRESTAT 56 CIMZIA ™ 56 ENDEAVOR II 56 IMPACT DCM clinical 56 tasimelteon 56 fosbretabulin 56 Multiple Ascending Dose 56 sapacitabine CYC# 56 CTAP# Capsules 56 investigational antiplatelet agent 56 CA9 SCAN 56 radiation sensitizer 56 Patient Enrollment 56 tolerated dose MTD 56 allosteric modulator NAM 56 mGluR2 positive 56 balsalazide tablet 56 ILLUMINATE 56 GVAX R 56 designated HVTN 56 assessing T DM1 56 Neo Urinary Conduit 56 carfilzomib 56 TAXUS Element Stent System 56 PrevOnco ™ 56 RG# [001] 56 multicenter Phase III 56 OLYMPIA registry 56 Aplidin R 56 perifosine KRX 56 JZP 6 56 Ereska 56 LEVADEX TM 56 CRLX# 56 3 registrational trial 56 evaluating nimotuzumab 56 REG1 Anticoagulation System 56 Tezampanel 56 Matrix Phase 2b 56 velafermin 56 PRE SURGE 56 induced macular edema 56 IMPACT DCM 56 CYT# 56 Randomized Phase 56 NYSE Amex PTN 56 ASSERT trial 56 TLK# 56 ONSOLIS 56 Rhucin ® recombinant 56 IV APAP 56 photoprotective drug 56 PrevOnco 56 fostamatinib 56 platinum refractory 56 Mr. Bentsur 56 inhaled AAT 56 Memryte 56 ISIS # 56 RESTORE CLI trial 56 CRD5 56 velaglucerase alfa 56 PROSTASCINT R 56 Hepatitis C HCV 56 DPX Survivac 56 thymalfasin 56 Chemophase 56 VIVITROL ® 56 Aeroquin 56 metastatic hormone refractory 56 Crofelemer budesonide foam 56 Androxal ® 56 Gentamicin Surgical Implant 56 AERx iDMS 56 BENLYSTA 56 oral rivaroxaban 56 Zemiva ™ 56 Marketing Authorisation Application 56 omega interferon 56 ARIKACE 56 ThermoDox R 56 Advaxis Phase 56 tivozanib 56 Stavzor 56 Viramidine 56 ofatumumab HuMax CD# 56 Second Pivotal Phase 56 Oglemilast 56 phase III SIMPADICO 56 injectable enzyme 56 RenalGuard System TM 56 Exherin 56 Onco TCS 56 sorafenib tablets 56 Acetavance 56 IRX 2 56 faropenem 56 RELOVAIR ™ 56 Cellegesic 56 Randomized Phase II 56 isavuconazole 56 ALN TTR# 56 antibody MAb 56 Triolex 56 Initiate Phase II 56 includes TOLAMBA TM 56 Telavancin 56 Opexa 56 masked placebo controlled 56 MNTX 56 Nasdaq RDEA 56 zileuton IV 56 pralatrexate 56 recombinant PSMA vaccine 56 NABTT 56 Phase III TRIST 56 ALTROPANE R 56 ALN TTR 55 BiTE antibody 55 HEPLISAV ™ 55 RDEA# 55 unblind 55 delta opioid receptor 55 tesetaxel 55 CAPACITY trials 55 Microplasmin 55 miconazole Lauriad R 55 SPARLON 55 Somatuline R Autogel R 55 TRO# 55 evaluating intravenous picoplatin 55 histamine dihydrochloride 55 histone deacetylase HDAC inhibitor 55 GTC recombinant human 55 Dapagliflozin 55 synthetic retinoid 55 Prednisporin 55 RhuDex ® 55 SCH # 55 Prefeasibility Study 55 INSPIRE Trial Phase III 55 Initiates Phase III 55 sulodexide 55 GRNVAC1 55 PI3K/Akt pathway inhibitor 55 Auxilium Pharma 55 Alnylam #x# 55 placebo controlled randomized 55 generation PNP inhibitor 55 otelixizumab 55 Inc. NASDAQ AVNR 55 atacicept 55 orBec R 55 lesinurad 55 Clonicel 55 PREOS 55 ALVESCO HFA 55 Alocrest 55 investigational monoclonal antibody 55 omecamtiv mecarbil formerly 55 Fodosine TM 55 SinuNase ™ 55 ZADAXIN 55 PROTECT AF 55 LEVADEX ™ 55 rilonacept 55 cetrorelix 55 LungExpress Dx TM 55 Onalta ™ 55 Rhucin R 55 albinterferon alfa 2b 55 Iluvien 55 Onyx Pharma 55 DASISION 55 Rezular 55 rindopepimut 55 Anthim 55 multicenter randomized clinical 55 PF # [002] 55 OMNARIS HFA 55 Altropane 55 HDL Selective Delipidation 55 Efficacy Results 55 CDP# 55 EFAPROXYN 55 Nasdaq OPTR 55 docetaxel Taxotere R 55 MINDSET 55 evaluating satraplatin 55 MEK Inhibitor 55 Phase 2b Trial 55 catheter occlusion 55 overactive bladder AA# 55 MOR# 55 tamibarotene 55 Initiates Phase II 55 TRANSDUR Bupivacaine 55 ritonavir boosted danoprevir 55 CD# CEA 55 ocrelizumab 55 ospemifene 55 AMD# [002] 55 Restanza TM 55 mipomersen 55 HCV RESPOND 2 55 BLOOM DM 55 OAB overactive bladder 55 ZALBIN 55 URG# 55 Orathecin 55 ATL# [001] 55 highly purified pasteurized 55 Phase III registrational 55 Nasdaq MAPP